Bausch Health Companies (BHC) Scheduled to Post Quarterly Earnings on Thursday

Bausch Health Companies (NYSE:BHC) is scheduled to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.74 per share for the quarter. Bausch Health Companies has set its FY 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.14. The business had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The firm’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.02 earnings per share. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Bausch Health Companies Price Performance

NYSE:BHC traded up $0.05 on Tuesday, reaching $8.93. 147,789 shares of the company’s stock were exchanged, compared to its average volume of 2,750,077. The firm has a market cap of $3.26 billion, a price-to-earnings ratio of -5.49 and a beta of 0.85. Bausch Health Companies has a 52 week low of $5.57 and a 52 week high of $11.46. The stock has a fifty day simple moving average of $9.31 and a 200-day simple moving average of $8.19.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on BHC shares. Piper Sandler increased their target price on shares of Bausch Health Companies from $7.00 to $9.00 and gave the stock a “neutral” rating in a research report on Monday. Royal Bank of Canada cut their price objective on shares of Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating for the company in a research report on Tuesday, April 23rd. Jefferies Financial Group dropped their target price on shares of Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Finally, StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $11.33.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.